Back to Resource Hub Article

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention

Participant dropout remains a significant challenge in clinical trials of anti-obesity medications. Reported attrition rates of 15-30% in major Phase III studies can reduce treatment exposure, weaken statistical power, and introduce bias, making the evidence harder to interpret.

Originally published in Applied Clinical Trials, this article from Signant Health’s clinical science team examines why participants withdraw from clinical trials of anti-obesity medications and which evidence-based strategies can improve retention. It makes the case that retention must be built into trial design from the outset, not addressed once participants begin leaving.

What you’ll learn 

  • Why participants leave anti-obesity medication trials, from gastrointestinal tolerability and perceived lack of efficacy to visit burden and unexpectedly rapid weight loss
  • Evidence-based strategies to improve participant engagement and retention
  • How adaptive, behavior-focused goal setting supports engagement and retention
  • How ePRO and visit data can flag at-risk participants early and trigger targeted support
  • What sponsors should build into trial design, from site training to real-time data quality oversight

Publication and authors 

Marcela Roy, MA, Executive Director, Clinical (Science & Medicine), Signant Health
Lauren Crooks, MSc, Associate Director, Clinical, Signant Health
Graham Ellis, MD, Clinical Vice President, Signant Health
Alan Kott, MUDR, Practice Lead, Data Analytics, Signant Health
Dawie Wessels, MD, Chief Medical Officer, Signant Health
Elias Ketiar, MD, MRCP, Clinical Vice President, Signant Health

Read the full article:

Patient Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention

DOWNLOAD THE ARTICLE

What if you could see dropout risk before it becomes withdrawal?

Signant has supported dozens of GLP-1 protocols across more than 35 countries. Our clinical science and analytics experts help sponsors build retention into obesity trials from the start, with engagement support, flexible visit options, and data-driven oversight.

Plan for retention before your first participant is enrolled.

Get notified on new marketing insights

Here mention the benefits of subscribing